Cargando…

An Evaluation of the Immunohistochemical Expression of Mismatch Repair Proteins (MSH2, MSH6, MLH1, and PMS2) in Prostate Adenocarcinoma

Background and objective Mismatch repair (MMR) proteins are an integral part of the cell cycle, and they play an important role in the genomic stability of the microsatellite complex. Microsatellite instability (MSI) is associated with Lynch and multi-tumor syndromes. Identifying patients with Lynch...

Descripción completa

Detalles Bibliográficos
Autores principales: Javeed, Saira, Chughtai, Anila, Zafar, Ghazi, Khalid, Fatima, Batool, Ayma, Chughtai, Akhtar S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9420449/
https://www.ncbi.nlm.nih.gov/pubmed/36051725
http://dx.doi.org/10.7759/cureus.27448
_version_ 1784777392410066944
author Javeed, Saira
Chughtai, Anila
Zafar, Ghazi
Khalid, Fatima
Batool, Ayma
Chughtai, Akhtar S
author_facet Javeed, Saira
Chughtai, Anila
Zafar, Ghazi
Khalid, Fatima
Batool, Ayma
Chughtai, Akhtar S
author_sort Javeed, Saira
collection PubMed
description Background and objective Mismatch repair (MMR) proteins are an integral part of the cell cycle, and they play an important role in the genomic stability of the microsatellite complex. Microsatellite instability (MSI) is associated with Lynch and multi-tumor syndromes. Identifying patients with Lynch syndrome is essential for screening, early detection, and surveillance of other Lynch syndrome-associated tumors. The role of MMR deficiency is well known in colorectal and endometrial adenocarcinoma. However, the role of MMR deficiency in prostatic adenocarcinoma is a matter of controversy. A few studies have been published to analyze the association between MMR deficiency and prostatic adenocarcinoma. In this study, we used immunohistochemistry to look into the expression of four MMR proteins in prostatic adenocarcinoma: MSH2, MSH6, MLH1, and PMS2. Methodology This was a cross-sectional descriptive study involving 74 cases of acinar prostatic adenocarcinoma, diagnosed with hematoxylin & eosin (H&E), over a period of six months between December 2021 and May 2022 at the Chughtai Institute of Pathology in Lahore, Pakistan. We performed the immunohistochemical (IHC) analysis and interpretation of four antibodies, i.e., MSH2, MSH6, MLH1, and PMS2. Results In our study, the age of the patients ranged from 50 to 98 years, with a mean age of 67.99 ± 9.59 years. The specimens were collected through transurethral resection of the prostate (TURP), transurethral vaporization of the prostate (TVP), core biopsy, and radical prostatectomy. Isolated loss of each MSH2 and PMS2 was noted in nine cases (12.20%) and MSH6 in two cases (2.70%). There was no loss noted for MLH1. Furthermore, simultaneous loss of MSH2/MSH6 was observed in one case (1.35%). Conclusion Our study findings revealed a low frequency of IHC expression of MMR proteins, especially the concurrent loss of paired MMR proteins. However, prostatic adenocarcinoma is associated with the isolated loss of MMR proteins. Thus, the present study does not warrant reflex testing/screening in every case of prostatic adenocarcinoma, because of its low frequency, which is probably suggestive of its sporadic pattern.
format Online
Article
Text
id pubmed-9420449
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-94204492022-08-31 An Evaluation of the Immunohistochemical Expression of Mismatch Repair Proteins (MSH2, MSH6, MLH1, and PMS2) in Prostate Adenocarcinoma Javeed, Saira Chughtai, Anila Zafar, Ghazi Khalid, Fatima Batool, Ayma Chughtai, Akhtar S Cureus Pathology Background and objective Mismatch repair (MMR) proteins are an integral part of the cell cycle, and they play an important role in the genomic stability of the microsatellite complex. Microsatellite instability (MSI) is associated with Lynch and multi-tumor syndromes. Identifying patients with Lynch syndrome is essential for screening, early detection, and surveillance of other Lynch syndrome-associated tumors. The role of MMR deficiency is well known in colorectal and endometrial adenocarcinoma. However, the role of MMR deficiency in prostatic adenocarcinoma is a matter of controversy. A few studies have been published to analyze the association between MMR deficiency and prostatic adenocarcinoma. In this study, we used immunohistochemistry to look into the expression of four MMR proteins in prostatic adenocarcinoma: MSH2, MSH6, MLH1, and PMS2. Methodology This was a cross-sectional descriptive study involving 74 cases of acinar prostatic adenocarcinoma, diagnosed with hematoxylin & eosin (H&E), over a period of six months between December 2021 and May 2022 at the Chughtai Institute of Pathology in Lahore, Pakistan. We performed the immunohistochemical (IHC) analysis and interpretation of four antibodies, i.e., MSH2, MSH6, MLH1, and PMS2. Results In our study, the age of the patients ranged from 50 to 98 years, with a mean age of 67.99 ± 9.59 years. The specimens were collected through transurethral resection of the prostate (TURP), transurethral vaporization of the prostate (TVP), core biopsy, and radical prostatectomy. Isolated loss of each MSH2 and PMS2 was noted in nine cases (12.20%) and MSH6 in two cases (2.70%). There was no loss noted for MLH1. Furthermore, simultaneous loss of MSH2/MSH6 was observed in one case (1.35%). Conclusion Our study findings revealed a low frequency of IHC expression of MMR proteins, especially the concurrent loss of paired MMR proteins. However, prostatic adenocarcinoma is associated with the isolated loss of MMR proteins. Thus, the present study does not warrant reflex testing/screening in every case of prostatic adenocarcinoma, because of its low frequency, which is probably suggestive of its sporadic pattern. Cureus 2022-07-29 /pmc/articles/PMC9420449/ /pubmed/36051725 http://dx.doi.org/10.7759/cureus.27448 Text en Copyright © 2022, Javeed et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Pathology
Javeed, Saira
Chughtai, Anila
Zafar, Ghazi
Khalid, Fatima
Batool, Ayma
Chughtai, Akhtar S
An Evaluation of the Immunohistochemical Expression of Mismatch Repair Proteins (MSH2, MSH6, MLH1, and PMS2) in Prostate Adenocarcinoma
title An Evaluation of the Immunohistochemical Expression of Mismatch Repair Proteins (MSH2, MSH6, MLH1, and PMS2) in Prostate Adenocarcinoma
title_full An Evaluation of the Immunohistochemical Expression of Mismatch Repair Proteins (MSH2, MSH6, MLH1, and PMS2) in Prostate Adenocarcinoma
title_fullStr An Evaluation of the Immunohistochemical Expression of Mismatch Repair Proteins (MSH2, MSH6, MLH1, and PMS2) in Prostate Adenocarcinoma
title_full_unstemmed An Evaluation of the Immunohistochemical Expression of Mismatch Repair Proteins (MSH2, MSH6, MLH1, and PMS2) in Prostate Adenocarcinoma
title_short An Evaluation of the Immunohistochemical Expression of Mismatch Repair Proteins (MSH2, MSH6, MLH1, and PMS2) in Prostate Adenocarcinoma
title_sort evaluation of the immunohistochemical expression of mismatch repair proteins (msh2, msh6, mlh1, and pms2) in prostate adenocarcinoma
topic Pathology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9420449/
https://www.ncbi.nlm.nih.gov/pubmed/36051725
http://dx.doi.org/10.7759/cureus.27448
work_keys_str_mv AT javeedsaira anevaluationoftheimmunohistochemicalexpressionofmismatchrepairproteinsmsh2msh6mlh1andpms2inprostateadenocarcinoma
AT chughtaianila anevaluationoftheimmunohistochemicalexpressionofmismatchrepairproteinsmsh2msh6mlh1andpms2inprostateadenocarcinoma
AT zafarghazi anevaluationoftheimmunohistochemicalexpressionofmismatchrepairproteinsmsh2msh6mlh1andpms2inprostateadenocarcinoma
AT khalidfatima anevaluationoftheimmunohistochemicalexpressionofmismatchrepairproteinsmsh2msh6mlh1andpms2inprostateadenocarcinoma
AT batoolayma anevaluationoftheimmunohistochemicalexpressionofmismatchrepairproteinsmsh2msh6mlh1andpms2inprostateadenocarcinoma
AT chughtaiakhtars anevaluationoftheimmunohistochemicalexpressionofmismatchrepairproteinsmsh2msh6mlh1andpms2inprostateadenocarcinoma
AT javeedsaira evaluationoftheimmunohistochemicalexpressionofmismatchrepairproteinsmsh2msh6mlh1andpms2inprostateadenocarcinoma
AT chughtaianila evaluationoftheimmunohistochemicalexpressionofmismatchrepairproteinsmsh2msh6mlh1andpms2inprostateadenocarcinoma
AT zafarghazi evaluationoftheimmunohistochemicalexpressionofmismatchrepairproteinsmsh2msh6mlh1andpms2inprostateadenocarcinoma
AT khalidfatima evaluationoftheimmunohistochemicalexpressionofmismatchrepairproteinsmsh2msh6mlh1andpms2inprostateadenocarcinoma
AT batoolayma evaluationoftheimmunohistochemicalexpressionofmismatchrepairproteinsmsh2msh6mlh1andpms2inprostateadenocarcinoma
AT chughtaiakhtars evaluationoftheimmunohistochemicalexpressionofmismatchrepairproteinsmsh2msh6mlh1andpms2inprostateadenocarcinoma